Susan Serrao

Gelsolin mitigates vascular damage by preventing release of IL-1β microparticles after trauma of high pressure and decompression. Gelsolin is non-immunosuppressive unlike current treatments to quell inflammatory cytokines. MORRISTOWN, N.J., April 8, 2021 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases based on a portfolio […]

MORRISTOWN, N.J., March 15, 2021 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases based on a portfolio built around gelsolin technology, announced today that it has completed enrollment for its Phase 2 study of hospitalized patients with severe COVID-19 pneumonia. This study assesses BioAegis’

MORRISTOWN, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through a portfolio built around gelsolin technology, announces publication of “Recombinant Human Plasma Gelsolin Improves Survival and Attenuates Lung Injury in a Murine Model of Multidrug-Resistant Pseudomonas aeruginosa Pneumonia.” Recombinant human plasma gelsolin

BioAegis Conducting COVID-19 Clinical Trial of Gelsolin Therapeutic Morristown, NJ, August 17, 2020 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through a portfolio built around gelsolin technology, announced today that recent publications of independent studies have reported that low levels of gelsolin are

Morristown, NJ, August 5, 2020 (GlobeNewswire) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through a portfolio built around gelsolin technology, announced today that it enrolled its first patient in its Phase 2 study of hospitalized patients with severe COVID-19 pneumonia. This study assesses BioAegis’ therapeutic,

MORRISTOWN, N.J., July 15, 2020 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., announces that it received regulatory clearance from The Spanish Agency for Medicines and Health Products (AEMPS) for its Phase 2 Proof of Concept study of its lead product, recombinant human plasma gelsolin (rhu-pGSN) in hospitalized patients with severe COVID-19 pneumonia. BioAegis expects to recruit

MORRISTOWN, N.J., June 23, 2020 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical-stage private company focused on developing therapies for infectious, inflammatory and degenerative diseases through a portfolio built around gelsolin technology, announces that its $5 million non-brokered bridge financing to accelerate its COVID-19 clinical trial was over-subscribed. Funding to Expedite Clinical Trial of COVID-19 TreatmentBioAegis